Here, it is also worth mentioning that ibrutinib-resistant MCL samples upregulate the mTOR signaling pathway (as well as genes involved in cell cycle regulation and MYC targets) compared to ibrutinib-sensitive cells (87). The gene discussed is MYC; the disease is mantle cell lymphoma.